Allurar CBL-514 Lipolysis: Binciken Mataki na 2
CBL‑514 wani allura ne da ake bincike wanda aka ƙera don haifar da apoptosis na sel ɗin kitse (adipocytes) a cikin ciki. Gwajin mataki na 2 da aka wallafa a Aesthetic Surgery Journal a 2025 ya haɗa da mahalarta 76 da aka raba ta bazuwar. An samu raguwar ƙimar kitse da aka auna ta hanyar ultrasound idan aka kwatanta da maganin saline, yayin da matsakaicin nauyin jiki ba ya sauyawa. Sakamakon na da sha'awa, amma ƙirar gwajin na da wasu manyan iyakoki. Wannan ƙididdiga na nuni da abin da gwajin ya tabbatar, abin da ba ya tabbatar, da wuraren da ake buƙatar ƙarin bincike.
Ba shawarar kiwon lafiya ba. CBL‑514 yana cikin bincike kuma ana ba shi ne daga masu binciken gwaji, ba a kan mutum kai tsaye ba.
Menene CBL‑514 (da abin da ba shi ba)
Sunan da ya dace shi ne CBL‑514; a kan yi kuskuren rubuta CL‑514. Allurar na fitowa daga kamfanin Caliway Biopharmaceuticals da ke New Taipei City, Taiwan. Ana gabatar da ita a matsayin allurar subcutaneous wadda ake yi a yankin da ake magancewa – a wannan gwajin, a cikin ciki. Ba maganin kari ba ne, ba kwayar baki ba, kuma ba samfurin da aka amince da shi don amfani ga jama'a ba. A lokacin da aka wallafa takardar, FDA ba ta amince da wannan samfur ba. Kayan da FDA ta amince da shi don rage kitse shi ne ATX‑101 (deoxycholic acid, Kybella), wanda ake amfani da shi ne kawai a yankin ƙasa da ƙirji (submental).
Takardar ba ta bayyana cikakken tsarin sinadaran ba, don haka babu jerin abubuwan da za a tantance.
Mafi muhimmancin tushen shine Gold M, Schlessinger J, Goodman GJ, Dayan S, DuBois J, Ling YF, Sheu AY, Ho WWS, Chou YC. Aesthet Surg J. 2025;45(6):611‑620 (doi:10.1093/asj/sjaf032; ClinicalTrials.gov NCT04897412). An buɗe shi a: https://pmc.ncbi.nlm.nih.gov/articles/PMC12080885/.
Hanyar aikin: rahoton kamfani, ba na mutane ba
Takardar mataki na 2a da ta gabata (Goodman et al., 2022) ƙarama ce kuma a buɗe‑label, ba tare da ƙungiyar placebo ba. Ta nuna cewa CBL‑514 yana hana kinase ɗin sel DYRK1b, yana ƙara aikin caspase‑3 da Bax/Bcl‑2, kuma yana haifar da apoptosis na adipocytes. Waɗannan hujjojin sun samo asali ne daga rahotannin sirri na Caliway da ba a wallafa ba.
Saboda haka, wannan hanya ta samo asali ne daga gwajin ba‑na‑mutane na kamfanin, ba a tabbatar da ita a cikin mutane ba a wannan gwaji. Hakanan ta bayyana mutuwar sel ɗin kitse a wuri, ba haɓakar tsarin metabolism ba, ba ƙone ƙalori ba, kuma ba raguwar nauyin jiki gaba ɗaya ba. Kiran “fat‑burning” daga masu tallata ƙwayoyin haɓaka jiki ba shi da tushe a nan.
Yadda aka gina gwajin mataki na 2
- Tsari: gwaji mai bazuwar, single‑blind, parallel‑group, da placebo‑controlled, an gudanar da shi daga Fabrairu 2022 zuwa Maris 2023 a cibiyoyi 5 a Amurka da Australia.
- Rarrabawa: an raba mahalarta a ratio na 2:1 tsakanin CBL‑514 da placebo (normal saline).
- Blind: an toshe gani ga mahalarta kawai, an yi amfani da shinge na gani. Masu bincike, ma’aikatan cibiyar, mai tallafa, da mai lura da lafiyar su, duk sun san wane magani aka ba kowane mahalarta. Ba double‑blind ba ne.
- Rawa: Caliway ta shiga cikin ƙirar gwajin, tattara bayanai, nazari da fassara, rubuta takarda, da kuma yanke shawarar gabatar da sakamakon.
- Sharuɗɗan cancanta: shekaru 18‑64, BMI tsakanin 18.5‑35, nauyin aƙalla 50 kg, zurfin fata a cikin ciki tsakanin 3‑8 cm, da lafiyar hanta, koda, zuciya da garkuwar jiki.
- Ka’ida ta daidaita nauyi: bambanci na kilogram 3 ko fiye daga farawa na haifar da dakatar da mahalarta.
Kima da jadawalin da aka yi amfani da su a gwajin
Kima da aka yi amfani da ita ita ce 2 mg/cm², wanda ke nufin har zuwa 600 mg a kowanne magani. Kowanne magani ya ƙunshi allurai 25‑50, bisa ga shawarar mai bincike, an ɗora su a tazara 2.45 cm. Kowanne allura ya ƙunshi 2.4 mL na CBL‑514 ko adadin daidai na saline. Mahalarta sun karɓi har zuwa magani huɗu a tazara makonni huɗu, sannan an bi su a makonni 4 da 8 bayan maganin ƙarshe. Wannan tsari na gwaji ne, ba don amfani kai ba.
Yadda aka auna kitse
An auna kitse ta hanyar ultrasound a wurare huɗu (4 cm da 10 cm daga dama da hagu na ma’aunin ciki). An ɗauki hotuna uku a kowane wuri, an yi matsakaici, kuma ƙwararrun masu yin ultrasound ne suka gudanar da aikin. An ƙididdige ƙimar ta hanyar ƙirga kubu: yanki 300 cm² da aka tantance a matsayin wurin magani an ninka da matsakaicin kaurin kitse. Masu bincike sun kuma yi amfani da hoton 3D. Babban manufa ita ce tantance adadin mahalarta da suka rasa aƙalla 150 mL a makonni 4 da 8 na bibiyar.
Sakamakon da aka samu
An tantance mutane 130, an shiga 81, daga ciki aka bazuwar 76 (CBL‑514 = 50, placebo = 26). An magance 75 (CBL‑514 = 49, placebo = 26). Daga cikin waɗannan 75, 38 suka kammala gwajin, 37 ba su kammala ba, wanda ke nuni da kaso na 49.3 % na rashin kammala. Dalilan sun haɗa da rasa bibiyar (6), janye kai (7), rashin daidaita nauyi (7), rashin iya bin jadawalin (6), da kuma mummunan sakamako (4).
Yawan mahalarta a ƙa'ida ta ITT (intention‑to‑treat) shi ne 76, yayin da a ƙa'ida ta PP (per‑protocol) kawai 30 ne.
Rukuni na CBL‑514 (n = 50) ya ƙunshi mata 94 % da fararen fata 86 %, matsakaicin shekaru 46.3, da matsakaicin BMI 27.77. Rukuni na placebo ya ƙunshi mata 80.8 %. Wannan ya nuna cewa gwajin ya fi mayar da hankali kan mata masu nauyi matsakaici da kitse a cikin ciki.
Sakamakon tasiri da ƙananan lambobi
Masu bincike sun bayyana cewa gwajin ya cika babban manufa da dukkan manufa na biyu. Ƙananan lambobi suna raguwa a bibiyar saboda rashin halartar wasu mahalarta; don haka ya kamata a yi la’akari da wannan lokacin karanta sakamako.
Aƙalla 150 mL an rasa (ITT):
- Makonni 4: CBL‑514 63.9 % (23/36; 95 % CI 46.22‑79.18) vs placebo 17.4 % (4/23; 95 % CI 4.95‑38.78); P < .001.
- Makonni 8: CBL‑514 69.6 % (16/23; 95 % CI 47.08‑86.79) vs placebo 0.0 % (0/16); P < .001.
Aƙalla 200 mL an rasa (ITT):
- Makonni 4: CBL‑514 58.3 % (21/36; 95 % CI 40.76‑74.49) vs placebo 8.7 % (2/23; 95 % CI 1.07‑28.04); P < .001.
- Makonni 8: CBL‑514 60.9 % (14/23; 95 % CI 38.54‑80.29) vs placebo 0.0 % (0/16); P < .001.
Bincike na ƙari aƙalla 250 mL: 44.4 % (16/36) a makonni 4 da 52.2 % (12/23) a makonni 8 a rukunin CBL‑514. Babu ɗaya daga cikin placebo da ya kai wannan.
Canjin matsakaici (ITT, least‑squares): bambanci tsakanin rukuni ya kasance −206.62 mL a makonni 4 (95 % CI −276.09 zuwa −137.16) da −216.28 mL a makonni 8 (95 % CI −288.28 zuwa −144.28), duka P < .001.
Rukuni PP (mutane 30 kawai): bambanci tsakanin rukuni ya kasance −312.08 mL a makonni 4 da −276.83 mL a makonni 8. Wannan ƙungiyar tana da matuƙar tacewa, don haka za ta iya nuna sakamako mafi kyau fiye da ITT.
Magunguna da ake buƙata: Daga cikin mahalarta CBL‑514 28 da suka kai aƙalla 150 mL, 12 sun cimma bayan magani 1, 10 bayan magani 2. Wannan na nufin 22 cikin 28 (kimanin 79 %) sun samu sakamako bayan magani 1 ko 2. Mafi girman raguwar da aka rubuta shine fiye da 750 mL a cikin mahalarta guda ɗaya.
Nauyi bai canza ba, kuma wannan shi ne ainihin batu
Matsakaicin nauyin jiki ya tsaya ba tare da canji ba. Mahalarta na CBL‑514 sun nuna ƙaruwa na +0.45 kg a makonni 4 da +0.02 kg a makonni 8, yayin da rukunin placebo ya rage −0.76 kg da −0.26 kg. Takardar ta ba da rahoton raguwar kitse a wuri ko da a cikin wasu mahalarta da suka ƙara fiye da 1 kg (babu cikakken bayani). Wannan na nuni da tasirin kitse a wuri, amma yana nuna cewa ƙimar nauyi ba ta da amfani wajen auna amfanin. Babu shaidar ƙona kitse a duk jiki.
Tsaron lafiya da iyakoki: karanta kafin ka karanta manyan labarai
Tsaron lafiya ya haɗa da rikodin abubuwan da suka faru bayan magani, gwaje‑gwajen dakin gwaje‑gwaje, sigogi, ECG, duba jiki, da kuma sakamako a wurin allura. Mahalarta huɗu sun janye saboda mummunan sakamako. Wannan takarda ba ta bayar da cikakken rarrabuwa na mummunan sakamako ba, don haka ya kamata a duba sashen tsaron lafiya da kyau.
Mahimman ƙuntatawa:
- Single‑blind kawai. Masu bincike da mai tallafa sun san wanene ya karɓi maganin.
- Haɗin gwiwar mai tallafa a duk ƙirar, nazari da wallafa.
- Rashin halarta mai yawa. Kusan rabi na mahalarta da aka magance ba su kammala, kuma rukuni PP ya ƙunshi mutane 30 kawai.
- Girman samfurin bincike ba tare da ƙididdigar ƙarfin gwaji ba, kuma ba a yi daidaiton gwaje‑gwaje da yawa ba.
- Lokacin bibiyar gajere: makonni 8 bayan magani na ƙarshe, don haka ba a san ɗorewa ba.
- Mafi yawa mata, don haka faɗaɗa zuwa maza ba shi da ƙarfi.
- Kwatanta kai tsaye. Masu bincike sun kwatanta sakamakon da gwaje‑gwajen cryolipolysis (misali, 264.8 mL a makonni 12 a guda ɗaya da 39.6 mL a watanni 2 a wani) kuma suka ce sakamakon CBL‑514 “ya dace da wanda aka samu da liposuction.” Wannan ra'ayi ne na masu rubutu; hanyoyin daban‑daban ne, ba a yi gwaji kai tsaye ba.
- Laxity na fata an lura da shi ne daga hotunan bayan magani, ba a auna a matsayin maƙasudin hukuma ba.
- Matsayin bincike. Ba a amince da shi ba, kuma babu tsarin allura da mutum zai yi da kansa.
Bincika jerin CBL-514
- Menene CBL-514? Shin yana ƙona kitse?
- Allurar cire kitse ta CBL-514: Menene kimiyya ke cewa?
- Yaya CBL-514 ke aiki? Ga kimiyya
- Shin CBL-514 na ƙona kitse da gaske? Ga abin da muka sani
- Kima na CBL-514 - menene kimiyya ke cewa?
Gabaɗaya
A wannan gwajin mataki na 2, CBL‑514 ya haifar da raguwar kitse da aka auna ta ultrasound a yankin ciki, yayin da matsakaicin nauyin jiki ya tsaya ba tare da canji ba idan aka kwatanta da saline. Hanyar ta samo asali ne daga gwajin ba‑na‑mutane na kamfanin wanda ba a wallafa ba. Shaidar da ake da ita ƙanana ce, tana da hannu daga mai tallafa, single‑blind, gajere, kuma adadin mahalarta da suka kammala ya yi ƙasa. Alamar tana nuna alamar da ke da ɗan alkawari, amma tana buƙatar ƙarin gwaje‑gwaje masu girma, tsawon lokaci, da ƙirar blind mafi ƙarfi, ba wani sakamako da aka riga aka yanke hukunci ba.